- Home
- COCH vs INMB Comparison
COCH vs INMB Comparison
Compare COCH & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COCH | INMB |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | 47 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.0M | 45.7M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | COCH | INMB |
|---|---|---|
| Price | $0.67 | $2.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $6.00 | $5.40 |
| AVG Volume (30 Days) | 283.8K | ★ 515.8K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000.00 |
| Revenue This Year | $1.58 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $0.36 | $1.09 |
| 52 Week High | $1.89 | $2.61 |
Technical Indicators
Market Signals| Indicator | COCH | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 48.76 | 58.66 |
| Support Level | $0.63 | $1.37 |
| Resistance Level | $0.74 | $2.17 |
| Average True Range (ATR) | 0.04 | 0.13 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 34.67 | 64.52 |
Price Performance
Historical ComparisonAbout COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.